For instance, in the context of homologous recombination deficiency (HRD), RAD51 foci can guide the use of PARP inhibitors (PARPis) in patients without mutations in HR-related genes suffering from breast and ovarian cancer [62,63,64]. The gene discussed is RAD51; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.